Back to top
more

Insulet Corporation (PODD)

(Real Time Quote from BATS)

$271.47 USD

271.47
261,217

-5.08 (-1.84%)

Updated Jul 26, 2021 09:49 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (196 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 161 - 180 ( 249 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 161

03/30/2015

Daily Note

Pages: 6

Insulet Strengthens Bench by Hiring Experienced CFO; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 162

03/30/2015

Daily Note

Pages: 6

Insulet Strengthens Bench by Hiring Experienced CFO; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 163

02/27/2015

Company Report

Pages: 8

Despite the Near-Term Challenges, Long-Term Thesis Remains Unchanged; Lowering PT to $34; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 164

02/23/2015

Daily Note

Pages: 17

MedTech Stocks To Watch This Week

Provider: Wedbush Securities Inc.

Price: 50.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 165

02/23/2015

Industry Report

Pages: 17

MedTech Stocks To Watch This Week

Provider: Wedbush Securities Inc.

Price: 50.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 166

01/08/2015

Company Report

Pages: 6

Negatively Pre-Announces, But Positive LT-Thesis Remains Intact; Lowering PT to $43; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 167

11/06/2014

Company Report

Pages: 7

Some Surprises, But We Stay the Course; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 168

10/30/2014

Daily Note

Pages: 5

International End-User OmniPod Sales Grew 60+% Over the Past 6 Months; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 169

10/28/2014

Daily Note

Pages: 5

Amgen Showcases OmniPod for Delivery of Neulasta; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 170

10/27/2014

Daily Note

Pages: 53

Initiating Coverage on Insulin Pump Companies

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 171

08/08/2014

Company Report

Pages: 9

OmniPod continues 35% year-over-year growth, guidance trimmed, maintain HOLD

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 172

08/05/2014

Company Report

Pages: 7

Insulin Pump Project: Historical survey of 4,500+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 173

05/08/2014

Company Report

Pages: 9

Inline Q1 on revs, loss per share above expectations, raise to HOLD from SELL

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 174

05/07/2014

Company Report

Pages: 8

Insulin Pump Project: Historical survey of 4,000+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 175

02/28/2014

Daily Note

Pages: 8

Inline Q4 on revs, loss per share above expectations, maintain SELL, PT to $34.50

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 176

02/21/2014

Company Report

Pages: 11

Insulin Pump Project: Historical survey of 4,000+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 177

11/08/2013

Company Report

Pages: 8

Inline Q3 on revs, EPS below expectations, next-gen OmniPod transition goes on

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 178

11/07/2013

Company Report

Pages: 7

Historical survey of 3,800+ pump users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 179

08/08/2013

Company Report

Pages: 8

Q2 inline, next gen OmniPod generating new interest, transitioning well

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 180

08/07/2013

Company Report

Pages: 7

Historical survey of 3,500+ pump users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party